MarketCapExport financials
Paratek Pharmaceuticals (PRTK)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Paratek Pharmaceuticals Cash Flow 2022-2008 | PRTK
Brief overview of Paratek Pharmaceuticals's cash movements
The comparison covers five available annual reports between 2018 and 2022.
Operating cash flow is negative at -$66.1 million, leaving internal funding capacity weak.
Core operations generated cash in 0 of five years. Frequent negative periods raise financial risk.
An additional $87.4 million became tied up in estimated working capital, equal to 54.5% of revenue.
Overall picture
Paratek Pharmaceuticals's cash profile looks stretched: weak operating cash flow limits investment, payouts and debt-servicing capacity.
Annual Cash Flow Paratek Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-66.1 M | -48.3 M | -103 M | -134 M | -81.2 M | -78.6 M | - | - | - | -14.8 M | -15.2 M | -5.71 M | -19.5 M | 830 K | - |
Depreciation & Amortization |
490 K | 391 K | 578 K | -1.29 M | -1.07 M | 1.27 M | 2.3 M | 714 K | 196 K | 98 K | 229 K | 357 K | 500 K | 550 K | - |
Accounts Payables |
5.31 M | 5.39 M | 1.81 M | 4.12 M | 2.09 M | 3.56 M | 4.42 M | 766 K | 489 K | 7.48 M | 1 M | 987 K | 598 K | - | - |
Accounts Receivables |
74.7 M | 29.4 M | 11.9 M | 8.48 M | 41 K | 5.04 M | - | 745 K | 4.43 M | 243 K | 168 K | 288 K | - | - | - |
Total Inventories |
16.6 M | 11 M | 14.6 M | 11.6 M | 598 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Paratek Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
9.31 M | 11.1 M | - | -46 M | -33.6 M | -19.1 M | - | -28.5 M | -54.7 M | -21.5 M | - | -79.6 M | -50.7 M | -30.3 M | - | -98.5 M | -70.4 M | -35.8 M | - | -62.2 M | -41.7 M | -19.1 M | - | -56.2 M | -40.7 M | - | - | - | - | - | - | - | - | - | - | -4.6 M | -1.78 M | -131 K | - | -9.36 M | -7.55 M | -4.27 M | - | -1.68 M | -8.18 M | -3.55 M | - | -13.1 M | -7.83 M | -4.29 M |
Depreciation & Amortization |
93 K | 47 K | - | 404 K | 275 K | 144 K | - | 313 K | 225 K | 110 K | - | 437 K | 264 K | 70 K | - | -1.12 M | -893 K | -485 K | - | -530 K | 290 K | 187 K | - | 979 K | 655 K | 301 K | - | 941 K | 583 K | 244 K | - | 544 K | 394 K | 272 K | - | 17 K | 11 K | 6 K | - | 82 K | 72 K | 41 K | - | 182 K | 129 K | 66 K | - | 290 K | 216 K | 114 K |
Accounts Payables |
2.95 M | 5.32 M | 5.31 M | 8.11 M | 2.26 M | 4.7 M | 5.39 M | 4.99 M | 2.59 M | 4.04 M | 1.81 M | 3.04 M | 5.58 M | 663 K | 4.12 M | 3.96 M | 2.51 M | 3.09 M | 2.09 M | 5.11 M | 2.67 M | 3.76 M | 3.56 M | 2.86 M | 3.27 M | 2.12 M | 4.42 M | 5.56 M | 7.91 M | 4.38 M | 766 K | 4 K | 321 K | 5 K | 489 K | 447 K | 1.04 M | 886 K | 7.48 M | 1.9 M | 376 K | 954 K | 1 M | 1.1 M | 1.01 M | 1 M | 987 K | 987 K | 987 K | 987 K |
Accounts Receivables |
42.3 M | 36.9 M | 74.7 M | 29.4 M | 28.5 M | 24.7 M | 29.4 M | 21.9 M | 55.6 M | 15.9 M | 11.9 M | 13 M | 8.66 M | 10.9 M | 8.48 M | 3.98 M | 2.56 M | 2.2 M | 41 K | 22 K | 19 K | 50 K | 5.04 M | 5.04 M | 5.04 M | 5.04 M | - | 230 K | 85 K | 488 K | 745 K | 270 K | 496 K | 391 K | 4.43 M | 4.43 M | 4.43 M | 4.43 M | 243 K | - | - | - | 168 K | - | - | - | 288 K | - | - | - |
Total Inventories |
11.4 M | 14 M | 16.6 M | 20.8 M | 13.1 M | 12.7 M | 11 M | 8.82 M | 7.95 M | 14.2 M | 14.6 M | 19.5 M | 17.6 M | 13.5 M | 11.6 M | 8.83 M | 7.57 M | 1.98 M | 598 K | 598 K | 598 K | 598 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Paratek Pharmaceuticals, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
$ 5.64 | 5.92 % | $ 691 M |  USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.99 | 4.33 % | $ 255 M | USA |
 |
Alector
ALEC
|
$ 2.19 | 2.1 % | $ 226 M | USA |
 |
Aligos Therapeutics
ALGS
|
$ 5.08 | 0.96 % | $ 50.2 M | USA |
 |
Alkermes plc
ALKS
|
$ 45.83 | 0.22 % | $ 7.55 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
$ 1.79 | 0.28 % | $ 395 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 248.37 | 0.14 % | $ 32.5 B | USA |
 |
Altimmune
ALT
|
$ 3.31 | 1.22 % | $ 292 M | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.93 | 0.52 % | $ 104 M | USA |
 |
Amgen
AMGN
|
$ 380.17 | 0.75 % | $ 205 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 23.96 | 0.74 % | $ 1.12 B | USA |
 |
Amarin Corporation plc
AMRN
|
$ 14.02 | 1.59 % | $ 5.82 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
$ 17.23 | 1.29 % | $ 5.4 B | USA |
 |
AbbVie
ABBV
|
$ 261.94 | 1.87 % | $ 463 B | USA |
 |
AnaptysBio
ANAB
|
$ 54.77 | 1.67 % | $ 1.58 B | USA |
 |
Anika Therapeutics
ANIK
|
$ 21.22 | 1.7 % | $ 304 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
$ 70.92 | 1.04 % | $ 1.42 B | USA |
 |
Aprea Therapeutics
APRE
|
$ 0.76 | 2.03 % | $ 4.97 M | USA |
 |
Aptevo Therapeutics
APVO
|
$ 1.87 | 2.75 % | $ 590 K | USA |
 |
AbCellera Biologics
ABCL
|
$ 11.04 | 1.38 % | $ 3.3 B |  Canada |
 |
Aquestive Therapeutics
AQST
|
$ 4.89 | 2.41 % | $ 523 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 15.23 | 3.39 % | $ 417 M |  Israel |
 |
Ardelyx
ARDX
|
$ 3.54 | 0.14 % | $ 853 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
$ 5.3 | 1.84 % | $ 192 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 24.35 | 1.95 % | $ 3.1 B | USA |
 |
Artelo Biosciences
ARTL
|
$ 5.15 | 1.1 % | $ 974 K | USA |
 |
Arvinas
ARVN
|
$ 8.44 | 0.41 % | $ 598 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 80.24 | 0.11 % | $ 10.7 B | USA |
 |
Assembly Biosciences
ASMB
|
$ 28.86 | 0.64 % | $ 324 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.25 | 6.87 % | $ 39 M | USA |
 |
Atara Biotherapeutics
ATRA
|
$ 9.49 | 1.17 % | $ 119 M | USA |
 |
Agenus
AGEN
|
$ 7.12 | 2.59 % | $ 212 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 16.3 | 1.26 % | $ 2.19 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.94 | 2.93 % | $ 516 M |  Britain |
 |
Atea Pharmaceuticals
AVIR
|
$ 5.34 | 0.47 % | $ 435 M | USA |
 |
Axon Enterprise
AXON
|
$ 491.2 | 2.47 % | $ 38.4 B | USA |
 |
Axsome Therapeutics
AXSM
|
$ 216.73 | 0.75 % | $ 10.8 B | USA |
 |
Aytu BioScience
AYTU
|
$ 2.0 | 0.5 % | $ 12.6 M | USA |
 |
BridgeBio Pharma
BBIO
|
$ 72.33 | 0.1 % | $ 13.9 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 8.2 | 0.92 % | $ 1.72 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.87 | 0.13 % | $ 268 M | Britain |
 |
Black Diamond Therapeutics
BDTX
|
$ 2.03 | 2.52 % | $ 115 M | USA |
 |
Beam Therapeutics
BEAM
|
$ 24.35 | 1.5 % | $ 2.41 B | USA |
 |
Biogen
BIIB
|
$ 217.62 | 0.22 % | $ 31.9 B | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 2.48 | 0.2 % | $ 6.11 B | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
$ 66.22 | 0.82 % | $ 12.7 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
$ 64.03 | 0.61 % | $ 130 B | USA |
 |
Benitec Biopharma
BNTC
|
$ 12.11 | 0.08 % | $ 498 M | USA |
 |
Burford Capital Limited
BUR
|
$ 4.35 | 1.13 % | $ 953 M | Britain |